Three-part report investigates rapid pipeline growth,
partnerships, clinical trials, and patient
access challenges in cancer treatment
LONDON, April 30,
2024 /PRNewswire/ -- BioWorld™ published
by Clarivate Plc (NYSE:CLVT), a leading global provider of
transformative intelligence, explores the growing investment in CAR
T therapy development in mainland China in a new series titled "China's CAR T market comes of age." The report
examines the dynamic realm of CAR T-cell therapies in China, including the rapid pipeline growth,
deals, clinical trials and challenging issues surrounding patient
access to very expensive and effective cancer therapeutics.
CAR T (Chimeric Antigen Receptor T-cell) therapy represents a
revolutionary approach to cancer treatment, harnessing the power of
the body's immune system to target and destroy cancer cells. As
this groundbreaking treatment gains traction in the pharmaceutical
sphere, the BioWorld special report provides valuable insights into
its present state and future potential. The report, authored
by Tamra Sami, Ruchita Kumar, and Sahil
Arora, covers three key topics:
- Part One: China's
investigator trials accelerate competitive CAR T
development
The exponential growth of China's CAR T market is projected to soar
from $72 million in 2022 to an
impressive $342 million over the next
decade. With over 400 CAR T therapies currently in the pipeline,
fueled by strategic collaborations between multinational pharma
giants and local biotechs, this segment promises unprecedented
opportunities for growth and innovation.
- Part Two: CAR T pipelines bloom to treat world's
largest cancer population
As of Jan.
31, 2024, there were more than 300 CAR T trials registered
in China, surpassing the U.S. and
becoming the country with the most CAR T therapy clinical trials.
Among them, CD19 is the most frequently studied target. The rapid
evolution of CAR T-cell therapies in China has escalated over the past decade from
the start of the first clinical trials in 2013 to the country
becoming an established host for CAR T-cell-related trials by
2017.
- Part Three: China
grapples with providing access to CAR T therapies
The
process of manufacturing autologous T-cell therapies is
technically challenging when compared with other oncology drugs,
making the overall cost of developing CAR T therapies significantly
higher. A challenging reimbursement environment for drugs in
China also means that most
patients will have to pay out of pocket to access CAR T therapies.
Taken together, complex logistics – production, manufacturing and
supply chain – and complicated administration requirements are key
bottlenecks that inflate the input costs involved in developing
these specialized treatment options.
Lynn Yoffee, Publisher,
BioWorld, said: "China's quest
to become the world leader in biopharmaceutical innovation may be
gaining momentum even as countries sort through complex licensing
and patent rights challenges. One thing is clear: China is now the leader in studying CAR T
therapies with the most clinical trials, surpassing the U.S. How
patients will be able to pay for these expensive treatments out of
pocket given China's challenging
reimbursement system remains in question. The BioWorld special
report investigates how CAR T development is coming of age in a
country with the world's second-largest population."
For more exclusive in-depth coverage of the evolution of
China's CAR T landscape, visit
here.
Join the conversation and mention BioWorld
on X and LinkedIn as well as Clarivate
for Life Sciences & Healthcare on X
and LinkedIn.
About BioWorld
With writers and editors stationed around the globe, BioWorld
published by Clarivate, reports the breaking news - and provides
key perspective on hundreds of therapeutics and devices in
development, the companies behind those candidates, the business
development transactions that evolve the markets, and the
regulatory hurdles that both challenge and guard the processes.
BioWorld has a long tradition of excellence in journalism.
Collectively, the news services have been honored with 61 awards
dating back to 1998.
About Clarivate
Clarivate™ is a leading global provider of transformative
intelligence. We offer enriched data, insights & analytics,
workflow solutions and expert services in the areas of Academia
& Government, Intellectual Property and Life Sciences &
Healthcare. For more information, please
visit www.clarivate.com
Media Contact:
Catherine
Daniel
Director, External Communications, Life Sciences &
Healthcare
newsroom@clarivate.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bioworld-by-clarivate-explores-the-future-of-car-t-therapy-in-mainland-china-in-special-report-302130695.html
SOURCE Clarivate Plc